Gene delivery to the spinal cord: Comparison between lentiviral, adenoviral, and retroviral vector delivery systems

Ahmed A. Abdellatif, Jennifer L. Pelt, Richard L. Benton, Russell M. Howard, Pantelis Tsoulfas, Peipei Ping, Xiao-Ming Xu, Scott R. Whittemore

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Viral gene delivery for spinal cord injury (SCI) is a promising approach for enhancing axonal regeneration and neuroprotection. An understanding of spatio-temporal transgene expression in the spinal cord is essential for future studies of SCI therapies. Commonly, intracellular marker proteins (e.g., EGFP) were used as indicators of transgene levels after viral delivery, which may not accurately reflect levels of secreted transgene. This study examined transgene expression using ELISA after viral delivery of D15A, a neurotrophin with BDNF and NT-3 activities, at 1, 2, and 4 weeks after in vivo and ex vivo delivery using lentiviral, adenoviral, and retroviral vectors. Further, the inflammatory responses and viral infection patterns after in vivo delivery were examined. Lentiviral vectors had the most stable pattern of gene expression, with D15A levels of 536 ± 38 and 363 ± 47 pg/mg protein seen at 4 weeks after the in vivo and ex vivo delivery, respectively. Our results show that protein levels downregulate disproportionately to levels of EGFP after adenoviral vectors both in vivo and ex vivo. D15A dropped from initial levels of 422 ± 87 to 153 ± 18 pg/mg protein at 4 weeks after in vivo administration. Similarly, ex vivo retrovirus-mediated transgene expression exhibited rapid downregulation by 2 weeks post-grafting. Compared to adenoviral infection, macrophage activation was attenuated after lentiviral infection. These results suggest that lentiviral vectors are most suitable in situations where stable long-term transgene expression is needed. Retroviral ex vivo delivery is optional when transient expression within targeted spinal tissue is desired, with adenoviral vectors in between.

Original languageEnglish (US)
Pages (from-to)553-567
Number of pages15
JournalJournal of Neuroscience Research
Volume84
Issue number3
DOIs
StatePublished - Aug 15 2006
Externally publishedYes

Fingerprint

Transgenes
Spinal Cord
Genes
Spinal Cord Injuries
Down-Regulation
Proteins
Viral Genes
Macrophage Activation
Brain-Derived Neurotrophic Factor
Nerve Growth Factors
Virus Diseases
Retroviridae
Infection
Regeneration
Enzyme-Linked Immunosorbent Assay
Gene Expression

Keywords

  • Adenovirus
  • Gene therapy
  • Lentivirus
  • Retrovirus
  • Spinal cord injury

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Abdellatif, A. A., Pelt, J. L., Benton, R. L., Howard, R. M., Tsoulfas, P., Ping, P., ... Whittemore, S. R. (2006). Gene delivery to the spinal cord: Comparison between lentiviral, adenoviral, and retroviral vector delivery systems. Journal of Neuroscience Research, 84(3), 553-567. https://doi.org/10.1002/jnr.20968

Gene delivery to the spinal cord : Comparison between lentiviral, adenoviral, and retroviral vector delivery systems. / Abdellatif, Ahmed A.; Pelt, Jennifer L.; Benton, Richard L.; Howard, Russell M.; Tsoulfas, Pantelis; Ping, Peipei; Xu, Xiao-Ming; Whittemore, Scott R.

In: Journal of Neuroscience Research, Vol. 84, No. 3, 15.08.2006, p. 553-567.

Research output: Contribution to journalArticle

Abdellatif, AA, Pelt, JL, Benton, RL, Howard, RM, Tsoulfas, P, Ping, P, Xu, X-M & Whittemore, SR 2006, 'Gene delivery to the spinal cord: Comparison between lentiviral, adenoviral, and retroviral vector delivery systems', Journal of Neuroscience Research, vol. 84, no. 3, pp. 553-567. https://doi.org/10.1002/jnr.20968
Abdellatif, Ahmed A. ; Pelt, Jennifer L. ; Benton, Richard L. ; Howard, Russell M. ; Tsoulfas, Pantelis ; Ping, Peipei ; Xu, Xiao-Ming ; Whittemore, Scott R. / Gene delivery to the spinal cord : Comparison between lentiviral, adenoviral, and retroviral vector delivery systems. In: Journal of Neuroscience Research. 2006 ; Vol. 84, No. 3. pp. 553-567.
@article{8f253566c4fa45a7a77614f60458603e,
title = "Gene delivery to the spinal cord: Comparison between lentiviral, adenoviral, and retroviral vector delivery systems",
abstract = "Viral gene delivery for spinal cord injury (SCI) is a promising approach for enhancing axonal regeneration and neuroprotection. An understanding of spatio-temporal transgene expression in the spinal cord is essential for future studies of SCI therapies. Commonly, intracellular marker proteins (e.g., EGFP) were used as indicators of transgene levels after viral delivery, which may not accurately reflect levels of secreted transgene. This study examined transgene expression using ELISA after viral delivery of D15A, a neurotrophin with BDNF and NT-3 activities, at 1, 2, and 4 weeks after in vivo and ex vivo delivery using lentiviral, adenoviral, and retroviral vectors. Further, the inflammatory responses and viral infection patterns after in vivo delivery were examined. Lentiviral vectors had the most stable pattern of gene expression, with D15A levels of 536 ± 38 and 363 ± 47 pg/mg protein seen at 4 weeks after the in vivo and ex vivo delivery, respectively. Our results show that protein levels downregulate disproportionately to levels of EGFP after adenoviral vectors both in vivo and ex vivo. D15A dropped from initial levels of 422 ± 87 to 153 ± 18 pg/mg protein at 4 weeks after in vivo administration. Similarly, ex vivo retrovirus-mediated transgene expression exhibited rapid downregulation by 2 weeks post-grafting. Compared to adenoviral infection, macrophage activation was attenuated after lentiviral infection. These results suggest that lentiviral vectors are most suitable in situations where stable long-term transgene expression is needed. Retroviral ex vivo delivery is optional when transient expression within targeted spinal tissue is desired, with adenoviral vectors in between.",
keywords = "Adenovirus, Gene therapy, Lentivirus, Retrovirus, Spinal cord injury",
author = "Abdellatif, {Ahmed A.} and Pelt, {Jennifer L.} and Benton, {Richard L.} and Howard, {Russell M.} and Pantelis Tsoulfas and Peipei Ping and Xiao-Ming Xu and Whittemore, {Scott R.}",
year = "2006",
month = "8",
day = "15",
doi = "10.1002/jnr.20968",
language = "English (US)",
volume = "84",
pages = "553--567",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Gene delivery to the spinal cord

T2 - Comparison between lentiviral, adenoviral, and retroviral vector delivery systems

AU - Abdellatif, Ahmed A.

AU - Pelt, Jennifer L.

AU - Benton, Richard L.

AU - Howard, Russell M.

AU - Tsoulfas, Pantelis

AU - Ping, Peipei

AU - Xu, Xiao-Ming

AU - Whittemore, Scott R.

PY - 2006/8/15

Y1 - 2006/8/15

N2 - Viral gene delivery for spinal cord injury (SCI) is a promising approach for enhancing axonal regeneration and neuroprotection. An understanding of spatio-temporal transgene expression in the spinal cord is essential for future studies of SCI therapies. Commonly, intracellular marker proteins (e.g., EGFP) were used as indicators of transgene levels after viral delivery, which may not accurately reflect levels of secreted transgene. This study examined transgene expression using ELISA after viral delivery of D15A, a neurotrophin with BDNF and NT-3 activities, at 1, 2, and 4 weeks after in vivo and ex vivo delivery using lentiviral, adenoviral, and retroviral vectors. Further, the inflammatory responses and viral infection patterns after in vivo delivery were examined. Lentiviral vectors had the most stable pattern of gene expression, with D15A levels of 536 ± 38 and 363 ± 47 pg/mg protein seen at 4 weeks after the in vivo and ex vivo delivery, respectively. Our results show that protein levels downregulate disproportionately to levels of EGFP after adenoviral vectors both in vivo and ex vivo. D15A dropped from initial levels of 422 ± 87 to 153 ± 18 pg/mg protein at 4 weeks after in vivo administration. Similarly, ex vivo retrovirus-mediated transgene expression exhibited rapid downregulation by 2 weeks post-grafting. Compared to adenoviral infection, macrophage activation was attenuated after lentiviral infection. These results suggest that lentiviral vectors are most suitable in situations where stable long-term transgene expression is needed. Retroviral ex vivo delivery is optional when transient expression within targeted spinal tissue is desired, with adenoviral vectors in between.

AB - Viral gene delivery for spinal cord injury (SCI) is a promising approach for enhancing axonal regeneration and neuroprotection. An understanding of spatio-temporal transgene expression in the spinal cord is essential for future studies of SCI therapies. Commonly, intracellular marker proteins (e.g., EGFP) were used as indicators of transgene levels after viral delivery, which may not accurately reflect levels of secreted transgene. This study examined transgene expression using ELISA after viral delivery of D15A, a neurotrophin with BDNF and NT-3 activities, at 1, 2, and 4 weeks after in vivo and ex vivo delivery using lentiviral, adenoviral, and retroviral vectors. Further, the inflammatory responses and viral infection patterns after in vivo delivery were examined. Lentiviral vectors had the most stable pattern of gene expression, with D15A levels of 536 ± 38 and 363 ± 47 pg/mg protein seen at 4 weeks after the in vivo and ex vivo delivery, respectively. Our results show that protein levels downregulate disproportionately to levels of EGFP after adenoviral vectors both in vivo and ex vivo. D15A dropped from initial levels of 422 ± 87 to 153 ± 18 pg/mg protein at 4 weeks after in vivo administration. Similarly, ex vivo retrovirus-mediated transgene expression exhibited rapid downregulation by 2 weeks post-grafting. Compared to adenoviral infection, macrophage activation was attenuated after lentiviral infection. These results suggest that lentiviral vectors are most suitable in situations where stable long-term transgene expression is needed. Retroviral ex vivo delivery is optional when transient expression within targeted spinal tissue is desired, with adenoviral vectors in between.

KW - Adenovirus

KW - Gene therapy

KW - Lentivirus

KW - Retrovirus

KW - Spinal cord injury

UR - http://www.scopus.com/inward/record.url?scp=33746932893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746932893&partnerID=8YFLogxK

U2 - 10.1002/jnr.20968

DO - 10.1002/jnr.20968

M3 - Article

C2 - 16786574

AN - SCOPUS:33746932893

VL - 84

SP - 553

EP - 567

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 3

ER -